Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Impax Laboratories Inc (IPXL): Insiders Are Buying, Should You?

Page 1 of 2

Impax Laboratories Inc (NASDAQ:IPXL) has seen an increase in activity from the world’s largest hedge funds of late.

In the financial world, there are plenty of metrics market participants can use to track publicly traded companies. A couple of the most underrated are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the top picks of the elite hedge fund managers can outperform the market by a significant amount (see just how much).

Impax Laboratories Inc (NASDAQ:IPXL)Just as important, bullish insider trading sentiment is a second way to parse down the marketplace. Obviously, there are plenty of incentives for a bullish insider to downsize shares of his or her company, but just one, very clear reason why they would initiate a purchase. Many empirical studies have demonstrated the valuable potential of this method if “monkeys” understand where to look (learn more here).

With these “truths” under our belt, we’re going to take a glance at the key action surrounding Impax Laboratories Inc (NASDAQ:IPXL).

What have hedge funds been doing with Impax Laboratories Inc (NASDAQ:IPXL)?

At Q1’s end, a total of 21 of the hedge funds we track held long positions in this stock, a change of 40% from the first quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were increasing their holdings significantly.

According to our comprehensive database, Visium Asset Management, managed by Jacob Gottlieb, holds the biggest position in Impax Laboratories Inc (NASDAQ:IPXL). Visium Asset Management has a $52.5 million position in the stock, comprising 1.4% of its 13F portfolio. Sitting at the No. 2 spot is OrbiMed Advisors, managed by Samuel Isaly, which held a $50.4 million position; the fund has 1.2% of its 13F portfolio invested in the stock. Some other hedge funds that are bullish include Ken Griffin’s Citadel Investment Group, Kevin Kotler’s Broadfin Capital and Sanford J. Colen’s Apex Capital.

Consequently, some big names were breaking ground themselves. Visium Asset Management, managed by Jacob Gottlieb, established the largest position in Impax Laboratories Inc (NASDAQ:IPXL). Visium Asset Management had 52.5 million invested in the company at the end of the quarter. Sanford J. Colen’s Apex Capital also initiated a $18.5 million position during the quarter. The other funds with brand new IPXL positions are Stephen DuBois’s Camber Capital Management, Jeremy Green’s Redmile Group, and SAC Subsidiary’s Sigma Capital Management.

What do corporate executives and insiders think about Impax Laboratories Inc (NASDAQ:IPXL)?

Bullish insider trading is at its handiest when the primary stock in question has seen transactions within the past 180 days. Over the latest 180-day time frame, Impax Laboratories Inc (NASDAQ:IPXL) has seen 3 unique insiders buying, and 4 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Impax Laboratories Inc (NASDAQ:IPXL). These stocks are Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Pacira Pharmaceuticals Inc (NASDAQ:PCRX), and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). This group of stocks are in the drug manufacturers – major industry and their market caps are similar to IPXL’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!